1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd.

002393.SZ
Tianjin Lisheng Pharmaceutical Co.,Ltd.CN flagShenzhen Stock Exchange
14.53
CNY
-0.63
- -
3.74BMarket Cap
Tianjin Lisheng Pharmaceutical Co.,Ltd.
002393.SZ
(Shenzhen Stock Exchange)

Recent

price

14.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.63
3.26
3.65
3.42
2.53
2.54
2.75
3.36
4.89
5.26
3.94
3.57
3.72
3.72
4.34
4.51
3.47
Revenue per Share
0.73
1.13
0.97
0.96
0.3
0.37
0.37
0.38
0.6
0.61
0.03
0.4
0.3
1.17
0.6
1.35
1.24
Basic EPS, GAAP
0.42
-0.08
0.09
-0.08
-0.71
-0.02
0.12
0.42
0.19
0.58
-0.08
0.35
0.94
0.45
0.11
0.68
-0.1
Free Cash Flow per Basic Share
0.54
0.54
0.52
0.53
0.36
0.19
0.25
0.19
0.19
0.18
0.19
0.06
0.18
0.18
0.39
0.31
0.54
Dividend per Share
1.46
2.22
2.57
2.96
2.88
3.05
3.13
3.31
3.67
4.04
4.1
4.18
4.25
5.09
5.58
6.59
6.44
Book Value per Share
9.1
9.92
8.73
9.2
9.15
9.39
9.43
9.53
14.3
13.87
14.35
13.93
13.67
15.41
14.78
14.43
14.23
Tangible Book Value per Share
280
306
306
306
306
305
308
307
308
307
289
306
308
310
308
308
311
Basic Weighted Avg Shares
738
998
1,117
1,044
774
775
847
1,029
1,504
1,615
1,141
1,092
1,147
1,153
1,336
1,392
1,079
Sales/Revenue/Turnover
32.92
25.85
28.81
29.19
11.41
16.58
13.61
9.55
11.43
12.13
5.09
4.18
7.28
11.44
6.75
8.09
9.65
Operating Margin (%)
17
25
25
24
26
25
49
56
55
61
63
60
66
67
81
79
- -
Depreciation Expense
203
346
297
293
93
114
116
117
185
188
9
122
94
362
185
416
385
Net Income, GAAP
17.28
13.36
16.89
15.83
17.12
15.64
13.26
10.71
13.56
13.22
72.15
10.95
20.92
13.89
13.89
7.22
6.85
Effective Tax Rate (%)
27.56
34.67
26.6
28.05
12
14.74
13.65
11.35
12.3
11.65
0.76
11.18
8.16
31.38
13.81
29.91
35.7
Profit Margin (%)
2,255
2,349
1,781
1,701
1,308
1,080
993
1,495
1,617
1,749
1,741
1,804
1,895
2,192
2,313
2,568
2,570
Working Capital
- -
9
8
90
70
50
30
10
- -
- -
6
6
5
4
8
5
5
LT Debt
2,650
3,151
2,787
2,924
2,910
2,970
3,015
3,080
4,570
4,417
4,302
4,411
4,349
4,903
4,800
4,661
4,639
Total Equity
12.03
7.62
8.94
8.72
2.4
3.55
3.23
2.79
3.79
3.72
0.37
0.92
1.48
2.42
1.58
2.17
2.01
Return on Invested Capital (%)
43.86
58.78
38.78
31.61
9.29
11.46
11.31
11.11
16.17
15.28
0.71
9.68
7.06
24.43
10.87
21.08
19.42
Return on Capital (%)
69.41
63.66
40.51
34.59
10.39
12.63
12.22
11.81
17.25
15.87
0.71
9.89
7.23
25.05
11.2
22.2
20.37
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
41
39
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
309
309
309
Market Capitalization
6,137
5,714
6,139

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
3,330
3,299
Cash, Cash Equivalents & STI
- -
2,558
2,482
Accounts Receivable, Net
- -
255
298
Inventories
- -
215
225
Total Current Liabilities
- -
762
729
Payables & Accruals
- -
- -
- -
ST Debt
- -
41
39
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.5%
1.77%
-2.9%
Free Cash Flow
-36.57%
0.98%
508.58%
Net Income, GAAP
162.4%
331.42%
125.59%
Sales/Revenue/Turnover
7.63%
4.27%
4.18%
Total Cash Common Dividend
- -
- -
-19.85%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
365
380
279
312
1,336
2025
370
362
- -
385
1,392
2026
332
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
- -
- -
- -
0.6
2025
0.18
- -
- -
- -
1.35
2026
0.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.39
2025
- -
- -
- -
- -
0.31
2026
0.25
- -
- -
- -
- -
Similar Companies
Ilsung Is Co., Ltd. (003120.KS)
Juva Life Inc. (JUVAF)
Bal Pharma Limited (BALPHARMA.NS)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ)
Alimera Sciences, Inc. (ALIM)
Eisai Co., Ltd. (ESALY)
Business
Tianjin Lisheng Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, production, and sale of a wide range of pharmaceutical products. Founded in 1951 and headquartered in Tianjin, China, the company operates primarily in the medical and health industries, offering products in multiple forms including tablets, hard capsules, pills, freeze-dried powder injections, water injections, oral liquids, granules, films, biological agents, and active pharmaceutical ingredients (APIs). Its core product categories cover cardiovascular and cerebrovascular drugs, anesthetics, analgesics, anti-infective agents, antineoplastic and immune system drugs, endocrine and respiratory medications, digestive system medicines, genitourinary system treatments, and traditional Chinese medicines. Key brands include "Shoubishan" indapamide tablets, "Shifuni" cefdinil dispersible tablets, and various soft capsules such as those based on hemp seed extract. The company’s product portfolio spans 15 pharmaceutical categories with over 243 approved drug registrations. Tianjin Lisheng operates a comprehensive industrial layout integrating research, development, manufacturing, and marketing, servicing both domestic and international markets with a broad sales network across China and exports to global markets. It also provides one-stop contract manufacturing organization (CMO) services to support pharmaceutical innovation ecosystems, particularly in Tianjin. As a national high-tech enterprise and national green factory, it adheres to advanced sustainability and innovation standards. In terms of recent major developments, Tianjin Lisheng Pharmaceutical announced an equity buyback program worth approximately CNY 153 million in 2024 to optimize its capital structure. The company continues to focus strategically on expanding its product offerings in critical therapeutic areas such as cardiovascular health and anti-infectives while advancing its capabilities in biopharmaceutical production. It actively pursues "industrial operation plus capital operation" dual-drive strategies, enhancing its competitiveness through innovation and strategic capital deployment. The company also maintains active participation in clinical trials and drug pipeline development to strengthen its therapeutic arsenal. Tianjin Lisheng Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd. and maintains significant brand recognition and market presence in China’s pharmaceutical industry. The company has received multiple accolades such as recognition as a Model Socially Responsible Enterprise in Tianjin and awards for its high-quality antihypertensive product brands. Its operations and offerings contribute broadly to China's healthcare and pharmaceutical sectors. Overall, Tianjin Lisheng Pharmaceutical is a well-established, diversified pharmaceutical enterprise with a long history, focused product lines across key therapeutic areas, ongoing strategic growth initiatives, and a commitment to innovation and sustainability in its industry presence.